BidaskClub Downgrades Epizyme, Inc. (NASDAQ:EPZM) to Strong Sell
BidaskClub downgraded shares of Epizyme, Inc. (NASDAQ:EPZM) from a sell rating to a strong sell rating in a report published on Friday.
Other equities research analysts have also recently issued reports about the company. Cann reiterated a buy rating and issued a $26.00 target price on shares of Epizyme in a report on Tuesday, April 25th. Zacks Investment Research upgraded Epizyme from a hold rating to a buy rating and set a $18.00 target price for the company in a report on Tuesday, May 16th. HC Wainwright reiterated a buy rating on shares of Epizyme in a report on Friday, May 19th. Cowen and Company reiterated a buy rating on shares of Epizyme in a report on Wednesday, June 7th. Finally, Oppenheimer Holdings, Inc. set a $26.00 target price on Epizyme and gave the stock a buy rating in a report on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $23.75.
Shares of Epizyme (EPZM) traded down 1.75% during trading on Friday, reaching $11.20. The company’s stock had a trading volume of 36,575 shares. The stock’s market cap is $653.61 million. Epizyme has a one year low of $7.02 and a one year high of $18.50. The company has a 50-day moving average price of $13.82 and a 200-day moving average price of $14.30.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Epizyme had a negative return on equity of 55.41% and a negative net margin of 1,376.33%. On average, equities research analysts forecast that Epizyme will post ($2.42) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades Epizyme, Inc. (NASDAQ:EPZM) to Strong Sell” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-epizyme-inc-nasdaqepzm-to-strong-sell/1465931.html.
In other Epizyme news, insider Robert A. Copeland sold 2,500 shares of the stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $13.45, for a total value of $33,625.00. Following the completion of the sale, the insider now directly owns 34,038 shares in the company, valued at $457,811.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $16.11, for a total value of $241,650.00. Following the completion of the sale, the insider now owns 22,228 shares of the company’s stock, valued at $358,093.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,524 shares of company stock valued at $746,797. 25.20% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its stake in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in Epizyme during the first quarter worth approximately $175,000. Spark Investment Management LLC acquired a new stake in Epizyme during the second quarter worth approximately $215,000. Bank of America Corp DE boosted its stake in Epizyme by 45.4% in the first quarter. Bank of America Corp DE now owns 14,561 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 4,544 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in Epizyme during the fourth quarter worth approximately $351,000. Institutional investors own 81.63% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.